374 related articles for article (PubMed ID: 18949510)
41. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy.
Kahrilas PJ; Jonsson A; Denison H; Wernersson B; Hughes N; Howden CW
Gut; 2014 May; 63(5):720-6. PubMed ID: 23831734
[TBL] [Abstract][Full Text] [Related]
42. The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study.
Kim JH; Lee YC; Kim EH; Park JC; Shin SK; Lee SK; Jung DH; Park JJ; Youn YH; Park H
Gut Liver; 2019 Nov; 13(6):642-648. PubMed ID: 30970442
[TBL] [Abstract][Full Text] [Related]
43. Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment.
Chen J; Brady P
Gastroenterol Nurs; 2019; 42(1):20-28. PubMed ID: 30688703
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of gastroesophageal reflux symptoms in a large unselected general population in Japan.
Yamagishi H; Koike T; Ohara S; Kobayashi S; Ariizumi K; Abe Y; Iijima K; Imatani A; Inomata Y; Kato K; Shibuya D; Aida S; Shimosegawa T
World J Gastroenterol; 2008 Mar; 14(9):1358-64. PubMed ID: 18322948
[TBL] [Abstract][Full Text] [Related]
45. Prevalence and characteristics of acid gastro-oesophageal reflux disease in Jackhammer oesophagus.
Mallet AL; Ropert A; Bouguen G; Siproudhis L; Boutroux D; Bretagne JF; Brochard C
Dig Liver Dis; 2016 Oct; 48(10):1136-41. PubMed ID: 27453169
[TBL] [Abstract][Full Text] [Related]
46. Esophageal hypermotility: cause or effect?
Crespin OM; Tatum RP; Yates RB; Sahin M; Coskun K; Martin AV; Wright A; Oelschlager BK; Pellegrini CA
Dis Esophagus; 2016 Jul; 29(5):497-502. PubMed ID: 25893778
[TBL] [Abstract][Full Text] [Related]
47. Sleep disturbances associated with gastro-oesophageal reflux disease: prevalence and impact of treatment in French primary care patients.
Cadiot G; Delaage PH; Fabry C; Soufflet C; Barthélemy P
Dig Liver Dis; 2011 Oct; 43(10):784-7. PubMed ID: 21752736
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms.
Delshad SD; Almario CV; Chey WD; Spiegel BMR
Gastroenterology; 2020 Apr; 158(5):1250-1261.e2. PubMed ID: 31866243
[TBL] [Abstract][Full Text] [Related]
49. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients.
Rinsma NF; Farré R; Bouvy ND; Masclee AA; Conchillo JM
Neurogastroenterol Motil; 2015 Feb; 27(2):220-8. PubMed ID: 25348594
[TBL] [Abstract][Full Text] [Related]
50. [Heartburn: you can choose to support in the short term].
Camain JY; Wiesel PH; Peytremann-Bridevaux I
Rev Med Suisse; 2011 May; 7(296):1169. PubMed ID: 21721208
[No Abstract] [Full Text] [Related]
51. Exacerbation of gastroesophageal reflux symptoms after discontinuation of proton pump inhibitors is not associated with increased esophageal acid exposure.
Hoshikawa Y; Nikaki K; Sonmez S; Nakagawa K; Yazaki E; Sifrim D; Woodland P
Neurogastroenterol Motil; 2020 Jan; 32(1):e13735. PubMed ID: 31657519
[TBL] [Abstract][Full Text] [Related]
52. [Therapy of gastroesophageal reflux disease (GERD)].
Storr M
Med Monatsschr Pharm; 2011 Dec; 34(12):446-54; quiz 455-6. PubMed ID: 22233024
[TBL] [Abstract][Full Text] [Related]
53. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
54. Clinical value of random esophageal biopsies in patients with dysphagia and normal endoscopy who are treated with a proton pump inhibitor.
Kamionkowski S; Shibli F; Saleh S; Trujillo S; Mengalle E; El Mokahal A; Thomas C; Song G; Fass R
Dis Esophagus; 2024 Apr; 37(4):. PubMed ID: 38197434
[TBL] [Abstract][Full Text] [Related]
55. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease.
Gerson LB; Fass R
Clin Gastroenterol Hepatol; 2009 Apr; 7(4):372-8; quiz 367. PubMed ID: 19111949
[TBL] [Abstract][Full Text] [Related]
56. [Multicenter study of gastroesophageal reflux disease symptoms prevalence in outpatients in Russia].
Bordin DS; Abdulkhakov RА; Osipenko MF; Solovyeva AV; Abdulkhakov SR; Kirilenko NP; Butov MA; Berezina OI; Valitova ER; Safina DD; Alieva IM; Livzan MA; Sarsenbaeva AS; Tarasova GN; Embutnieks YV; Mubarakshina IR; Khayrullin IK; Kononova AG; Kolbasnikov SV; Maev IV
Ter Arkh; 2022 Jan; 94(1):48-56. PubMed ID: 36286919
[TBL] [Abstract][Full Text] [Related]
57. Prevalence of non-obstructive dysphagia in patients with heartburn and regurgitation.
Batista AO; Nascimento WV; Cassiani RA; Silva ACV; Alves LMT; Alves DC; Dantas RO
Clinics (Sao Paulo); 2020; 75():e1556. PubMed ID: 31994617
[TBL] [Abstract][Full Text] [Related]
58. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease.
Thomson RM; Armstrong JG; Looke DF
Chest; 2007 Apr; 131(4):1166-72. PubMed ID: 17426224
[TBL] [Abstract][Full Text] [Related]
59. Evidence-based treatment of frequent heartburn: the benefits and limitations of over-the-counter medications.
McRorie JW; Gibb RD; Miner PB
J Am Assoc Nurse Pract; 2014 Jun; 26(6):330-9. PubMed ID: 24825071
[TBL] [Abstract][Full Text] [Related]
60. Prospective Study of Gastroesophageal Reflux, Use of Proton Pump Inhibitors and H2-Receptor Antagonists, and Risk of Hearing Loss.
Lin BM; Curhan SG; Wang M; Jacobson BC; Eavey R; Stankovic KM; Curhan GC
Ear Hear; 2017; 38(1):21-27. PubMed ID: 27556519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
